Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. URGN
stocks logo

URGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
41.45M
+68.74%
-0.489
-38.93%
43.62M
+115.34%
-0.507
-44.93%
53.20M
+119.69%
-0.357
-66.03%
Estimates Revision
The market is revising Downward the revenue expectations for UroGen Pharma Ltd. (URGN) for FY2025, with the revenue forecasts being adjusted by -8.31% over the past three months. During the same period, the stock price has changed by 28.60%.
Revenue Estimates for FY2025
Revise Downward
down Image
-8.31%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.44%
In Past 3 Month
Stock Price
Go Up
up Image
+28.60%
In Past 3 Month
Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 39.40 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 39.40 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.280
sliders
Low
31.00
Averages
39.40
High
55.00
Current: 24.280
sliders
Low
31.00
Averages
39.40
High
55.00
Piper Sandler
Overweight
initiated
$36
2025-08-19
Reason
Piper Sandler
Price Target
$36
2025-08-19
initiated
Overweight
Reason
As previously reported, Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target. Investors are starting to gain more confidence in the Zusduri launch, but the firm thinks the Street still underestimates peak sales potential in LG-IR-NMIBC and overestimates intellectual property risk to the -102/-103 franchise, the analyst contends. The firm sees early commercial launch datapoints, combined with updates from the Phase 3 UTOPIA trial of UGN-103, driving "meaningful upside" over the next 12-18 months.
Piper Sandler
NULL -> Overweight
initiated
$36
2025-08-18
Reason
Piper Sandler
Price Target
$36
2025-08-18
initiated
NULL -> Overweight
Reason
Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target.
H.C. Wainwright
Buy
downgrade
$50 -> $40
2025-08-11
Reason
H.C. Wainwright
Price Target
$50 -> $40
2025-08-11
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on UroGen Pharma to $40 from $50 and keeps a Buy rating on the shares. The firm revised long-term sales projections post the Q2 report.
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$50
2025-06-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$50
2025-06-17
upgrade
Neutral -> Buy
Reason
Guggenheim
NULL -> Buy
upgrade
$15 -> $30
2025-06-13
Reason
Guggenheim
Price Target
$15 -> $30
2025-06-13
upgrade
NULL -> Buy
Reason
Scotiabank
Outperform
upgrade
$23 -> $47
2025-06-13
Reason
Scotiabank
Price Target
$23 -> $47
2025-06-13
upgrade
Outperform
Reason
Scotiabank raised the firm's price target on UroGen Pharma to $47 from $23 and keeps an Outperform rating on the shares. The firm is increasing its FDA approval likelihood from 60% to 100% and raised its price target based on its current view of a peak ZUSDURI market opportunity of about $1B, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Urogen Pharma Ltd (URGN.O) is -15.70, compared to its 5-year average forward P/E of -4.14. For a more detailed relative valuation and DCF analysis to assess Urogen Pharma Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.14
Current PE
-15.70
Overvalued PE
-1.57
Undervalued PE
-6.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.60
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.89
Undervalued EV/EBITDA
-8.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.35
Current PS
0.00
Overvalued PS
6.28
Undervalued PS
2.42
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 573.47% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 194.83% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 573.47% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

URGN News & Events

Events Timeline

(ET)
2025-11-06
08:02:48
UroGen Pharma Reveals Initial Findings from Phase 3 UTOPIA Study
select
2025-11-06
08:01:49
UroGen Pharma Announces Q3 Earnings Per Share of 69 Cents, Exceeding Consensus Estimate of 68 Cents
select
2025-10-27 (ET)
2025-10-27
08:14:43
UroGen Pharma Reveals Permanent HCPCS Code for ZUSDURI Assigned by CMS
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
10-04NASDAQ.COM
D. Boral Capital Continues to Recommend Buying UroGen Pharma (URGN)

  • Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for UroGen Pharma, with a projected one-year price target of $34.42/share, indicating a potential upside of 97.96% from its current price of $17.39/share.

  • Fund Sentiment and Ownership Changes: There has been a 6.91% increase in the number of funds reporting positions in UroGen Pharma, with notable increases in ownership from firms like Rtw Investments and Jefferies Financial Group, while total shares owned by institutions decreased by 4.24% over the last three months.

[object Object]
Preview
4.0
08-19SeekingAlpha
Summit Takes Neutral Stance on Risk/Reward Dynamics as Piper Launches Coverage on Biotech Cancer Stocks

  • Piper Sandler's Coverage Launch: Piper Sandler initiated coverage on several cancer-focused biotech companies, giving a Neutral rating to Summit Therapeutics (SMMT) due to perceived high investor expectations and downside risks.

  • Revolution Medicines Rating: Revolution Medicines (RVMD) received an Overweight rating with a target price of $75 per share, driven by positive data for its lead asset daraxonrasib in treating pancreatic ductal adenocarcinoma.

  • Tango Therapeutics Potential: Analyst Kelsey Goodwin expressed optimism about Tango Therapeutics (TNGX), assigning an Overweight rating and a target of $11 per share, citing potential for its PRMT5-inhibitor TNG462 in various cancers.

  • UroGen Pharma Outlook: UroGen Pharma (URGN) was also rated Overweight with a target of $36 per share, as confidence grows around the market launch of its bladder cancer drug Zusduri and upcoming clinical updates.

[object Object]
Preview
4.0
08-11Benzinga
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $40

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Urogen Pharma Ltd (URGN) stock price today?

The current price of URGN is 24.28 USD — it has decreased -0.29 % in the last trading day.

arrow icon

What is Urogen Pharma Ltd (URGN)'s business?

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

arrow icon

What is the price predicton of URGN Stock?

Wall Street analysts forecast URGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for URGN is 39.40 USD with a low forecast of 31.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Urogen Pharma Ltd (URGN)'s revenue for the last quarter?

Urogen Pharma Ltd revenue for the last quarter amounts to 27.48M USD, increased 9.04 % YoY.

arrow icon

What is Urogen Pharma Ltd (URGN)'s earnings per share (EPS) for the last quarter?

Urogen Pharma Ltd. EPS for the last quarter amounts to -0.69 USD, increased 25.45 % YoY.

arrow icon

What changes have occurred in the market's expectations for Urogen Pharma Ltd (URGN)'s fundamentals?

The market is revising Downward the revenue expectations for UroGen Pharma Ltd. (URGN) for FY2025, with the revenue forecasts being adjusted by -8.31% over the past three months. During the same period, the stock price has changed by 28.60%.
arrow icon

How many employees does Urogen Pharma Ltd (URGN). have?

Urogen Pharma Ltd (URGN) has 235 emplpoyees as of December 05 2025.

arrow icon

What is Urogen Pharma Ltd (URGN) market cap?

Today URGN has the market capitalization of 1.14B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free